Your analysis is very similar to the numbers I hav

Your analysis is very similar to the numbers I have come up with.

I believe there was one dropout. If you recall, one of the initial 9 patients had a failure of her chemo port which required her to be removed from the trial.

Not sure where I got this from (so thank you in advance to whomever posted this long ago) but it was a nice refresher given the break we've had from cancer data. It's the creatv microtech (our diagnostic partner for cancer) poster on CAMLs and CTCs

http://www.creatvmicrotech.com/Documents/Post...CO2018.pdf

Quote:

---

CAMLs are specialized myeloid polyploid cells transiting the circulation of patients in various types of solid malignancies whose size increase is prognostic for survival1-3. While CAMLs are easy to identify
by their large size and polyploid nucleus, they appear to present as stem cell like phenotype with multiple heterogeneous epithelial, myeloid, and angiogenic markers. CTCs are cancer cells that originate from a primary solid tumor and are found transiting the circulatory system. While CTCs have been shown to be an indicator of metastatic malignant disease and predict survival outcomes in late stage patients, CTCs are not detected in all disease stages and rare a number of cancers (e.g.NSCLC and Esophageal)

---

Quote:

---

In a multivariate analysis, CAML size was the most predictive variable for OS and independent of other clinical variables, while CTC presence was associated with metastasis

---